Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

Table 3 Derivate study parameters in treatment groups and in overall patients (mean  ±  SE)

	Units	Overall	Group T	Group V
mMd*ALT	IU/dL per month	-0.57 ± 0.05	-0.63 ± 0.09	-0.52 ± 0.05
mMd*HOMA-IR	units/mo	-9.63 ± 0.94 × 10-2	-13.7 ± 1.32 × 10-2	-5.3 ± 0.64 × 10-2
mMd*TG	mg/dL per month	-1.79 ± 0.10	-1.99 ± 0.16	-1.58 ± 0.11
mMd*TC	mg/dL per month	-0.03 ± 0.03	-0.12 ± 0.05	0.06 ± 0.02
md*BMI	units	0.03 ± 0.36	0.11 ± 0.47	-0.05 ± 0.57
md*sBP	mmHg	-21.13 ± 1.13	-21.35 ± 1.68	-20.90 ± 1.54
md*dBP	mmHg	-19.18 ± 1.43	-19.65 ± 2.15	-18.67 ± 1.91
md*NAS	point	-0.92 ± 0.14	-1.43 ± 0.19	-0.38 ± 0.17
md*Fibrosis	point	-0.46 ± 0.11	-0.75 ± 0.13	-0.15 ± 0.18

mMd*ALT: Mean monthly decrease of ALT; mMd*HOMA-IR: Mean monthly decreases for HOMA-IR; mMd*TG: Mean monthly decrease of plasma triglycerides; mMd*TC: Mean monthly decrease of total cholesterol; md*BMI: Mean decrease of BMI; md*sBP: Mean decrease of systolic blood pressure; md*dBP: Mean decrease of diastolic blood pressure; md*NAS: The mean decrease for NAS; md*Fibrosis: Mean decrease for fibrosis score.